Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs Eclipse Medical Wellness

Two GLP-1 desks, one scoreboard. We put ShedRx and Eclipse Medical Wellness head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 400 · Grade C

Eclipse Medical Wellness

Visit Eclipse Medical Wellness Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 55 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make Eclipse Medical Wellness a bad call — it's best for readers who want colorado residents wanting clinician-led glp-1 care with labs (medication billed separately). Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
40
Supply Reliability
86
75
Transparency
84
23
Access Breadth
85
42
Clinical Oversight
85
88
Track Record
86
75
ShedRxBrief Score 87 · 55Eclipse Medical Wellness

Price, coverage & the tracker

ShedRxEclipse Medical Wellness
Brief Score87/100 (B+)55/100 (C)
Semaglutide$199/moNot disclosed
Tirzepatide$299/moNot disclosed
CoverageNot disclosed1 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Eclipse Medical Wellness: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.